Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 9/20 | 0.69 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | GOT1 | P17174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499400 | 0.86 | RHEB (0.73) | RHEBTRPA1DRD2DRD4DRD3 | |
| SCHEMBL13915642 | 0.84 | RHEB (0.59) | RHEBTRPA1DRD2DRD4DRD3 | |
| SCHEMBL9047954 | 0.84 | RHEB (0.72) | RHEBTRPA1MEN1MAPTMAPK1 | |
| SCHEMBL20536163 | 0.82 | RHEB (0.68) | RHEBTRPA1MEN1MAPTMAPK1 | |
| SCHEMBL20535840 | 0.82 | RHEB (1.00) | RHEBTRPA1 | |
| SCHEMBL30740391 | 0.80 | RHEB (0.55) | RHEBTRPA1MEN1MAPTMAPK1 | |
| SCHEMBL21225623 | 0.80 | RHEB (0.55) | RHEBTRPA1MEN1MAPTMAPK1 | |
| SCHEMBL23709718 | 0.79 | RHEB (0.79) | RHEBTRPA1DRD2DRD4DRD3 | |
| SCHEMBL20536057 | 0.79 | TRPA1 (0.74) | RHEBTRPA1DRD2DRD4DRD3 | |
| SCHEMBL7809978 | 0.79 | RHEB (0.54) | RHEBTRPA1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178051-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| CN-121606615-A | Medicine for treating colon cancer and preparation method and application thereof | 华中科技大学同济医学院附属同济医院 | 2026-03-06 | — | — | CN | disclosed |
| WO-2024178051-A3 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024178051-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2024178051-A2 | TRYPTAMINE DERIVATIVES | CAAMTECH, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| CN-109970794-B | S-substituted-3-indole thiophosphate derivative and preparation method and application thereof | 厦门大学 | 2020-07-03 | — | — | CN | disclosed |
| WO-2018191146-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| EP-1931631-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007041023-A1 | 1- (1H- INDOL- 1-YL) -3- (METHYLAMINO) -1- PHENYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072897-A1 | Phenylaminopropanol derivatives and methods of their use | COMT, PNMT, GLS | RHEB 2200/4885TRPA1 554/4885DRD2 99/4885 |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | RHEB 1/4885TRPA1 4835/4885DRD2 4183/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | RHEB 1/4885TRPA1 4877/4885DRD2 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.